



Phase II Demonstration Projects



Stepping It Up: Testing Interventions to Improve Medication Use Quality in Ambulatory Pharmacies





Phase II: Primary Research Objectives



- **Test the effectiveness of one or more pharmacist-based interventions to improve medication use, using PQA's 15 Quality Measures and Pharmacy Consumer Experience Survey**
- **Create/refine standardized pharmacy performance quality reports**
- **Assess the cost-effectiveness of interventions for pharmacy managers and payers**
- **Build the case for reimbursement of cost-effective medication quality improvement services**



Phase II: Secondary Objectives



- **Test P4P or other financial incentives for pharmacist reimbursement; or develop specifications for P4P actuarial model**
- **Determine causes of low PQA quality scores**
- **Evaluate the impact of quality scores on health outcomes**
- **Measure any negative effects of providing intervention**
- **Evaluate the scalability of the use of quality measures in large settings (e.g., multi-site)**



PQA's Call for Letters of Intent (LOI)



- **Launched a 3-year, multi-million dollar grant development plan to initiate multiple Phase II demonstration projects**
- **Sought LOIs from interested collaborative teams, led by at least one PQA member**
- **Team would be P.I. on federal applications, and PQA would take lead on corporate and foundation proposals**

Why the Marriage Between PQA and a Collaborative Team?



- **Collaborative Teams**
 - Expert researchers, real-world practice sites, and creative approaches to *test interventions to improve medication use and patient outcomes by measuring and moving PQA quality measures*
- **PQA**
 - Develop, refine, test, validate, maintain, disseminate, and promote medication use measures nationally
 - Foster communication among Phase II Teams

**Adds national dimension to proposals, which is desired by
AHRQ & Corporate Funders**



Federal Grant Partnership Models



- **Collaborative Model**
 - One Phase II partner as P.I. on joint federal application that includes PQA and other proposed Phase II teams
- **Independent Model**
 - Each Phase II partner submits individual federal grant application as P.I. with PQA in supportive role as collaborator on each



PQA's Role as Partner



- **Supply and maintain 15 PQA initial measures**
- **Move forward current and new measure concepts for testing and validation**
- **Liaison with demo projects, coordinate learning**
- **Network and communication across sites, interface with other stakeholders, disseminate best practices**
- **Submit PQA measures for NQF endorsement**
- **Solicit funding from non-government entities**



Funding Opportunities



- **Currently Four open AHRQ Announcements & expect more to be announced by AHRQ and NIH**
 - Two Comparative Effectiveness Research RFAs (up to \$10M) from stimulus package
 - Two quality-focused Program Announcements (up to \$2.5M)
- **Foundations & Other Non-Govt. Entities**
 - Amgen, Cardinal Foundation, Rite Aid Foundation, Heinz Foundation, Sanofi-Aventis, Novartis, Abbott, and eventually Commonwealth Fund and Robert Wood Johnson

Selection of PQA Partners



**Call for Letters of Intent to Partners
(July 28, 2009)**



**Receipt of 12 LOIs
4 Phase I + 8 New
(September 21, 2009)**



**Independent Review Committee
Scored Letters of Intent
(October 2009)**



**Individual Discussions with Partners
on Strategy, Timeline, and Proposal
(October/November 2009)**



PQA Review Selection Committee



Co-Chairs of PQA Research Coordinating Council (ex-officio): Eleanor Perfetto, Kristina Yu-Isenberg

Members:

Anne Burns, APhA

Cathy Carroll, Comprehensive Pharmacy Services

William Doucette, University of Iowa

Patrick Gleason, Prime Therapeutics

Julie Kuhle, Iowa Foundation for Medical Care

Leticia Mocygemba, Virginia Commonwealth Univ.

Karen Rascati, University of Texas



PQA Research Coordinating Council Members



Co-Chairs:

Eleanor Perfetto, Pfizer Inc., Kristina Yu-Isenberg, Novartis

Members:

Steve Blackwell, CMS

Anne Burns, RPh, APhA

Cathy Carroll, Two Rivers Psychiatric Hospital

Patrick Gleason, Prime Therapeutics

Jean-Venable Goode, VCU School of Pharmacy

Brian Isetts, University of Minnesota College of Pharmacy

David Nau, Humana, Inc.

Anthony Provenzano, SUPERVALU Pharmacies

Michael Rupp, Northwestern University

N. Lee Rucker, AARP

Bruce Sherman, The Goodyear Tire & Rubber Co.

Scott Smith, AHRQ

Brad Tice, PharmMD Solutions, LLC

Mary Helen Tran, Schering-Plough Corp.



Scoring System: LOI Proposals



- PI/Team Experience/Expertise: 30 points
- Strength of Environment/Org Capabilities: 25 points
- Objectives Align with PQA's: 25 points
- Willingness to Collaborate w/ PQA: 10 points
- Established relationships with funders: 10 points



Proposed Collaborative Teams for Phase II Projects



- Highmark/Rite-Aid/CECity/U of Pittsburgh*
- Humana/U of Florida
- Outcomes Pharmaceutical/Kerr Drug/U of NC-Chapel Hill*
- Pharmacy Society of WI/U of WI/WI Medicaid*
- PharmMD Solutions/PerformRx/PACE Program
- Purdue University/Regenstrief Institute/Wishard Health Services*
- U of AZ/AZ Healthcare Cost Containment System
- U of IL-Chicago/U of Miami-Humana Research Center/
SUPERVALU Inc.

***Phase I Demo Sites**



PQA: Next Steps



Corporate and Foundation Grants

- Secured commitments of **\$300,000** (over 3 years) from Community Pharmacy Foundation and **\$100,000** from Pfizer for Year One (1) of Phase II Projects
- Launched major effort targeting 10 Foundation and Corporate funders for Phase II Projects
 - Leveraging existing relationships of any Phase II teams
 - Identifying other funding opportunities

AHRQ Grants

- Collaborating with Phase II Partners on their applications

PQA Points of Contact



- Eleanor Perfetto:
eleanor.perfetto@pfizer.com
- Kristina Yu-Isenberg:
kristina-yu.isenberg@novartis.com
- Laura Cranston:
lcranston@PQAalliance.org

THANK YOU!